Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹500 | ₹100 |
Expense Ratio | 1.85 | 1.36 |
NAV | ₹33.42 | ₹199.81 |
Fund Started | 08 Jan 2018 | 07 May 2007 |
Fund Size | ₹3994.38 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 1% if redeemed within 3 months. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 0.67% | 7.71% |
3 Year | 24.28% | 26.63% |
5 Year | 27.45% | 29.55% |
1 Year
3 Year
5 Year
Equity | 97.88% | 93.60% |
Cash | 2.12% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
Glenmark Pharmaceuticals Ltd. | 3.11% |
Indian Bank | 2.99% |
UNO Minda Ltd. | 2.58% |
Blue Star Ltd. | 2.53% |
Tube Investments Of India Ltd. | 2.39% |
Nippon Life India Asset Management Ltd. | 2.26% |
JK Cement Ltd. | 2.24% |
IDFC First Bank Ltd. | 2.22% |
Union Bank of India | 2.15% |
APL Apollo Tubes Ltd. | 2.13% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Krishna Sanghavi | Chirag Setalvad |
Start Date | 07 Feb 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to generate long term capital appreciation & provide long-term growth opportunities by investing in a portfolio constituted of equity & equity related securities and derivatives predominantly in mid cap companies. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 08 Jan 2018 | 07 May 2007 |
Description
Launch Date